#2026/702NHS Pharmacy Reimbursement Changes for Certain Vaccines
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law expands the list of centrally purchased vaccines that can be reimbursed by the NHS at a zero or nominal product price when supplied or administered through pharmaceutical services in England. It adds vaccines used against meningococcal disease, including groups A, C, W and Y and group B, as well as vaccines against tetanus, diphtheria and polio, where the existing conditions are met. The practical effect is on pharmacy contractors and local pharmaceutical service providers: payment rules can reflect that these vaccines may be supplied centrally rather than bought by the pharmacy at normal market cost.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds meningococcal ACWY vaccines to the zero or nominal NHS reimbursement price arrangements
- Adds meningococcal B vaccines where the existing conditions are met
- Adds tetanus, diphtheria and polio vaccines where the existing conditions are met
Obligations
What this law requires
From 20 July 2026, apply the zero or nominal product reimbursement rules in regulation 91A to centrally purchased drugs or medicines used to vaccinate or immunise people against meningococcal disease caused by Neisseria meningitidis groups A, C, W and Y or group B, where the existing conditions in regulation 91A(3) are satisfied.
From 20 July 2026, apply the zero or nominal product reimbursement rules in regulation 91A to centrally purchased drugs or medicines used to vaccinate or immunise people against tetanus, diphtheria and polio, where the existing conditions in regulation 91A(3) are satisfied.